FDA approved a lower dose of Jevtana (cabazitaxel, 20 mg/m2 every 3 weeks) in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing treatment regimen. Cabazitaxel (25 mg/m2 every 3 weeks) was approved for this indication in 2010.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
